Ghanem, H., Cornelison, A. M., Garcia-Manero, G., Kantarjian, H., Ravandi, F., Kadia, T., . . . Jabbour, E. (2013). Decitabine Can Be Safely Reduced after Achievement of Best Objective Response in Patients with Myelodysplastic Syndrome.
Dyfyniad Arddull ChicagoGhanem, Hady, et al. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. 2013.
Dyfyniad MLAGhanem, Hady, et al. Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. 2013.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.